Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Middle District of Florida on behalf of shareholders of Apyx Medical Corporation who purchased shares between August 1, 2018 and April 1, 2019.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (2) as a result, the clinical study did not support the Company’s application for regulatory clearance; (3) as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until June 17, 2019 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
KUZNICKI LAW PLLC
445 Central Avenue, Suite 344, Cedarhurst, NY 11516
Phone: (347) 696-1134
Cell : (347) 690-0692
Fax : (347) 348-0967
© 2019 All Rights Reserved.